| scholarly article | Q13442814 |
| P2093 | author name string | R Charles Coombes | |
| Sami Shousha | |||
| Safiye Osman | |||
| Eric O Aboagye | |||
| David M Vigushin | |||
| Adil Al-Nahhas | |||
| Sajinder K Luthra | |||
| Laura M Kenny | |||
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| P304 | page(s) | 10104-10112 | |
| P577 | publication date | 2005-11-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods | |
| P478 | volume | 65 |
| Q36727598 | 18F-FLT Positron Emission Tomography/Computed Tomography Imaging in Pancreatic Cancer: Determination of Tumor Proliferative Activity and Comparison with Glycolytic Activity as Measured by 18F-FDG Positron Emission Tomography/Computed Tomography Imag |
| Q55461622 | 18F-fluorothymidine-pet imaging of glioblastoma multiforme: effects of radiation therapy on radiotracer uptake and molecular biomarker patterns. |
| Q36217442 | 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma: a pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki-67 activity and histopathologic response |
| Q36533964 | A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688 |
| Q48813461 | A multifractal approach to space-filling recovery for PET quantification |
| Q48517118 | ANG1005 for breast cancer brain metastases: correlation between 18F-FLT-PET after first cycle and MRI in response assessment. |
| Q40101346 | Application of the multicellular tumour spheroid model to screen PET tracers for analysis of early response of chemotherapy in breast cancer |
| Q53483629 | Assessment of therapy response in malignant tumours with 18F-fluorothymidine. |
| Q59796302 | Associations Between PET Parameters and Expression of Ki-67 in Breast Cancer |
| Q24301636 | Binding of ATP to TK1-like enzymes is associated with a conformational change in the quaternary structure |
| Q47442773 | Correlations of (18)F-fluorothymidine uptake with pathological tumour size, Ki-67 and thymidine kinase 1 expressions in primary and metastatic lymph node colorectal cancer foci |
| Q37989743 | Development and experimental medicine applications of PET in oncology: a historical perspective |
| Q35195500 | Development of radiotracers for oncology--the interface with pharmacology |
| Q91942629 | Dual time point [18F]FLT-PET for differentiating proliferating tissues vs non-proliferating tissues |
| Q33924541 | Dynamic small-animal PET imaging of tumor proliferation with 3'-deoxy-3'-18F-fluorothymidine in a genetically engineered mouse model of high-grade gliomas |
| Q80413759 | Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT |
| Q35169980 | Early detection of tumor response by FLT/microPET Imaging in a C26 murine colon carcinoma solid tumor animal model |
| Q37418581 | Evaluation of 18F-fluorothymidine positron emission tomography ([18F]FLT-PET/CT) methodology in assessing early response to chemotherapy in patients with gastro-oesophageal cancer |
| Q46867338 | Evaluation of 2'-deoxy-2'-[18F]fluoro-5-methyl-1-beta-L: -arabinofuranosyluracil ([18F]-L: -FMAU) as a PET imaging agent for cellular proliferation: comparison with [18F]-D: -FMAU and [18F]FLT. |
| Q39367887 | Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose- and 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography as biomarkers of therapy response in platinum-resistant ovarian cancer |
| Q33750115 | Evaluation of FLT-PET-CT as an imaging biomarker of proliferation in primary breast cancer. |
| Q34207614 | Evaluation of limited blood sampling population input approaches for kinetic quantification of [18F]fluorothymidine PET data |
| Q87214202 | FDG-PET/CT and FLT-PET/CT for differentiating between lipid-poor benign and malignant adrenal tumours |
| Q61806254 | FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab |
| Q30414100 | Heptamethine cyanine based (64)Cu-PET probe PC-1001 for cancer imaging: synthesis and in vivo evaluation |
| Q39643573 | High-glycolytic cancers and their interplay with the body’s glucose demand and supply cycle |
| Q89483641 | How Long of a Dynamic 3'-Deoxy-3'-[18F]fluorothymidine ([18F]FLT) PET Acquisition Is Needed for Robust Kinetic Analysis in Breast Cancer? |
| Q38631164 | IPET study: an FLT-PET window study to assess the activity of the steroid sulfatase inhibitor irosustat in early breast cancer. |
| Q57110625 | Imaging Tumor Proliferation in Breast Cancer: Current Update on Predictive Imaging Biomarkers |
| Q53496753 | Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. |
| Q36396755 | Imaging in cancer therapy and drug development. |
| Q33993075 | Importance of quantification for the analysis of PET data in oncology: review of current methods and trends for the future |
| Q39604614 | Improved detection and measurement of low levels of [18F]fluoride metabolized from [18F]-labeled pyrimidine nucleoside analogues in biological samples |
| Q37077354 | In vivo imaging of cellular proliferation in renal cell carcinoma using 18F-fluorothymidine PET |
| Q37236103 | Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics |
| Q30594766 | Introduction to the analysis of PET data in oncology |
| Q37349950 | Kinetic analysis of 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) in head and neck cancer patients before and early after initiation of chemoradiation therapy |
| Q34648592 | Limits of [18F]-FLT PET as a biomarker of proliferation in oncology |
| Q35633693 | Measuring proliferation in breast cancer: practicalities and applications |
| Q31119175 | Metabolic and molecular imaging in neuro-oncology. |
| Q48946602 | Methodological considerations in quantification of 3'-deoxy-3'-[18F]fluorothymidine uptake measured with positron emission tomography in patients with non-small cell lung cancer |
| Q38134094 | Molecular PET imaging for biology-guided adaptive radiotherapy of head and neck cancer |
| Q34496670 | Molecular imaging in cancer treatment |
| Q46076481 | Molecular imaging of proliferation in vivo: positron emission tomography with [18F]fluorothymidine |
| Q53010775 | Monitoring Tumor Response After Histone Deacetylase Inhibitor Treatment Using 3'-Deoxy-3'-[18F]-fluorothymidine PET. |
| Q48039426 | Monitoring Tumor Response after Liposomal Doxorubicin in Combination with Liposomal Vinorelbine Treatment Using 3'-Deoxy-3'-[18F]Fluorothymidine PET. |
| Q53169426 | Monitoring early response to taxane therapy in advanced breast cancer with circulating tumor cells and [(18)F] 3´-deoxy-3´-fluorothymidine PET: a pilot study. |
| Q43653298 | Monitoring tumor response with radiolabeled nucleoside analogs in a hepatoma-bearing mouse model early after doxisome(®) treatment |
| Q35700192 | Novel Approaches to Imaging Tumor Metabolism |
| Q37401153 | PET Radiotracers for Imaging the Proliferative Status of Solid Tumors |
| Q37784771 | PET/CT in cancer research: from preclinical to clinical applications. |
| Q30794621 | Parametric imaging of ¹⁸F-fluoro-3-deoxy-3-L-fluorothymidine PET data to investigate tumour heterogeneity. |
| Q28540476 | Phosphorylation status of thymidine kinase 1 following antiproliferative drug treatment mediates 3'-deoxy-3'-[18F]-fluorothymidine cellular retention |
| Q26768486 | Positron Emission Tomography in Breast Cancer |
| Q34697688 | Positron emission tomography imaging of cancer biology: current status and future prospects |
| Q35959380 | Proliferation PET image to characterize pathological spatial features in patients with non-small cell lung cancer: a pilot study. |
| Q34346931 | Quantitative assessment of dynamic PET imaging data in cancer imaging |
| Q57795439 | Relative skeletal distribution of proliferating marrow in the adult dog determined using 3'-deoxy-3'-[ F]fluorothymidine |
| Q34860276 | Reproducibility of quantitative 18F-3'-deoxy-3'-fluorothymidine measurements using positron emission tomography |
| Q28080621 | Role of positron emission tomography for the monitoring of response to therapy in breast cancer |
| Q34203953 | Specific biomarkers of receptors, pathways of inhibition and targeted therapies: clinical applications. |
| Q39042001 | Spectral Analysis of Dynamic PET Studies: A Review of 20 Years of Method Developments and Applications |
| Q36717905 | Targeted anti-mitotic therapies: can we improve on tubulin agents? |
| Q42419554 | The future of imaging: developing the tools for monitoring response to therapy in oncology: the 2009 Sir James MacKenzie Davidson Memorial lecture |
| Q34907192 | The role of DNA synthesis imaging in cancer in the era of targeted therapeutics |
| Q37201183 | Theoretical Analysis of Penalized Maximum-Likelihood Patlak Parametric Image Reconstruction in Dynamic PET for Lesion Detection. |
| Q36070106 | Tumour microenvironment heterogeneity affects the perceived spatial concordance between the intratumoural patterns of cell proliferation and 18F-fluorothymidine uptake |
| Q84463211 | Uptake decrease of proliferative PET tracer 18FLT in bone marrow after carbon ion therapy in lung cancer |
| Q36382036 | Validity of simplified 3'-deoxy-3'-[18F]fluorothymidine uptake measures for monitoring response to chemotherapy in locally advanced breast cancer |
| Q34100855 | Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL |
| Q55286904 | [18F]FDG and [18F]FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer. |
| Q36858129 | [18F]FDG and [18F]FLT uptake in human breast cancer cells in relation to the effects of chemotherapy: an in vitro study. |
| Q51009203 | ¹⁸F-FLT PET/CT as an imaging tool for early prediction of pathological response in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy: a pilot study. |
Search more.